AKRO
NASDAQAkero Therapeutics Inc.
News · 26 weeks10%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- SECSEC Form 15-12G filed by Akero Therapeutics Inc.15-12G - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form 25-NSE filed by Akero Therapeutics Inc.25-NSE - Akero Therapeutics, Inc. (0001744659) (Subject)
- INSIDERDirector Heyman Tomas J. returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Xu Yuan returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERPresident and CEO Cheng Andrew returned 436,837 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Harrison Seth Loring returned 293,762 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Graham G. Walmsley returned 1,302,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Judy Chou returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Scientific Officer Rolph Timothy returned 282,149 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Iwicki Mark T returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Technology Officer Gangloff Scott A. returned 26,351 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Financial Officer White William Richard returned 57,752 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Development Officer Yale Catriona returned 74,800 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Henderson Jane returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDEROfficer Lamy Patrick returned 29,891 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Operating Officer Young Jonathan returned 260,189 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form POSASR filed by Akero Therapeutics Inc.POSASR - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECAkero Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Akero Therapeutics, Inc. (0001744659) (Filer)
AKRO FAQ
7 questionsWhat does Akero Therapeutics Inc. do?
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin...Where does AKRO stock trade?
Akero Therapeutics Inc. (AKRO) is listed on NASDAQ.What sector and industry is AKRO in?
Akero Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Akero Therapeutics Inc. go public?
Akero Therapeutics Inc. (AKRO) completed its IPO in 2019.What are analysts saying about AKRO?
Akero Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2025-09-04. Recent price targets cluster around $3000.00.What companies are similar to AKRO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AKRO side-by-side with any of them on Quantisnow.How can I track AKRO on Quantisnow?
Quantisnow aggregates Akero Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKRO to receive live email and push alerts on every new disclosure.